Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 10;7:e2200594. doi: 10.1200/PO.22.00594

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 3. — Spectrum of gene alterations targeted with targeted therapies in (A) young (50 years and younger) and (B) older (older than 50 years) patients in our cohort. Among patients who received targeted therapy, the majority in both age groups received targeted therapy directed at FGFR2 fusions or IDH1 mutations. Gene names without the type of alteration indicated refer to mutations of those genes. ALK, anaplastic lymphoma kinase; Amp, amplification; HER2, human epidermal growth factor receptor 2; MET, mesenchymal-epithelial transition factor.